Drug Trial Radar · NCT05094336
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
329
Actual
Start
Feb 1, 2022
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.
Conditions
- Advanced MTAP-null Solid Tumors
Interventions
AnvumetostatDrug
Anvumetostat: Orally via tablet
DocetaxelDrug
Docetaxel: Intravenous infusion
Comparator Anvumetostat Test TabletDrug
Comparator Anvumetostat test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator Anvumetostat test tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: 28 days
- Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Up to approximately 3 years
- Part 3: Objective Response Rate (ORR)Time frame: Up to approximately 3 years
Locations
75 sites in 14 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
California Research Institute
Glendale, California
Fomat Medical Research
Oxnard, California
University of California at SF
San Francisco, California
D and H Cancer Research Center
Margate, Florida
Boca Raton Clinical Research Medical Center Inc
Tamarac, Florida
Goshen Health Systems
Goshen, Indiana
Indiana University
Indianapolis, Indiana
Community Health Network MD Anderson Cancer Center - North
Indianapolis, Indiana
University of Maryland Medical Center
Baltimore, Maryland
American Oncology Partners, PA
Bethesda, Maryland
Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan
Washington University
St Louis, Missouri
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Northwell Health Monter Cancer Center
Lake Success, New York
New York University Grossman School of Medicine and New York University Langone Hospitals
New York, New York
Duke University
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Sanford Oncology Clinic and Pharmacy
Sioux Falls, South Dakota
Sarah Cannon Research Institute
Dallas, Texas
Center for Oncology and Blood Disorders
Houston, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Lumi Research
Kingwood, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas
University of Virginia Cancer Center
Charlottesville, Virginia
Virginia Cancer Specialists PC
Fairfax, Virginia
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia
Epworth Healthcare
East Melbourne, Victoria, Australia
Peter MacCallum Cancer Centre
Parkville, Victoria, Australia
Medizinische Universitaet Graz
Graz, Austria
Landeskrankenhaus Salzburg
Salzburg, Austria
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, Belgium
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Belgium
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.